• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Indonesia·Healthcare·LABS.JK
Share

UBC Medical Indonesia Tbk. Stocks

IDR 157Last Updated 07.08.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

IDR 35.79M

IDR 157
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

UBC Medical Indonesia Tbk (LABS.JK) serves as a key supplier of medical devices throughout Indonesia. The company's operations are structured into two primary divisions: Medical Disposables and Consumables, and Diagnostics and Equipment. Its comprehensive product lineup includes advanced solutions for next-generation molecular analysis, AI-driven retina diagnostics, infectious disease detection, HPV DNA testing, real-time PCR technology, TB management systems, and newborn screening. Established in 2014, UBC Medical Indonesia Tbk is headquartered in Jakarta Timur, Jakarta, and operates as a subsidiary under the ownership of PT Optel Investama Mulia.

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITD.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

08.08.2026 12:15

Ukraine has promised the U.S. not to attack the CPC infrastructure in the Black Sea — Bloomberg

08.08.2026 03:20

Billionaire Ekman Identified the Main Risk for Investors in the Anthropic and OpenAI IPOs

08.08.2026 02:52

U.S. stocks posted their best weekly gain since mid-April. The S&P 500 hit a new record high.

08.08.2026 02:36

OpenAI has suspended development of a new AI model due to cybersecurity risks

08.08.2026 01:46

The U.S. Senate has approved new sanctions against Russia. It may be difficult for the bill to pass the full Congress.

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026